PeptideScanner retained ClinicalTrials.gov record NCT01982240 at 2026-07-30T20:42:14.439Z. Its registry update date was 2019-12-26, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT01093768 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-12-17, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT03840278 at 2026-11-16T01:42:39.027Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03584087 at 2026-11-15T21:47:40.408Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT04189900 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01440803 at 2026-07-30T20:42:14.438Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02937558 at 2026-07-30T20:42:14.438Z. Its registry update date was 2019-12-10, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03551873 at 2026-07-30T20:43:27.317Z. Its registry update date was 2019-11-22, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT00538694 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00540072 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01778556 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-11-13, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT03177798 at 2026-11-15T22:04:12.435Z. Its registry update date was 2019-10-29, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT01097044 at 2026-07-30T20:44:36.694Z. Its registry update date was 2019-10-28, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT01865760 at 2026-07-30T20:44:36.695Z. Its registry update date was 2019-10-28, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02969590 at 2026-07-30T20:44:36.693Z. Its registry update date was 2019-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02597803 at 2026-11-16T01:44:56.605Z. Its registry update date was 2019-10-17, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT03533179 at 2026-07-30T20:44:36.691Z. Its registry update date was 2019-10-17, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00254397 at 2026-07-30T20:44:36.700Z. Its registry update date was 2019-10-16, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04053270 at 2026-07-30T20:44:36.678Z. Its registry update date was 2019-10-10, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT00114114 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT01061775 at 2026-07-30T20:44:36.699Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03120520 at 2026-07-30T20:44:36.699Z. Its registry update date was 2019-10-04, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT01709110 at 2026-07-30T20:45:58.285Z. Its registry update date was 2019-09-23, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02768571 at 2026-11-16T17:33:14.861Z. Its registry update date was 2019-09-20, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT01605136 at 2026-07-30T20:45:58.280Z. Its registry update date was 2019-09-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT00628550 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-09-17, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02904759 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02905682 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT03352869 at 2026-07-30T20:45:58.274Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01614093 at 2026-11-16T00:59:19.138Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT02488057 at 2026-07-30T20:47:16.573Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01785849 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT01788046 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-20, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT02238366 at 2026-11-15T21:49:16.513Z. Its registry update date was 2019-07-25, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00669162 at 2026-07-30T20:48:52.438Z. Its registry update date was 2019-07-24, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01896232 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-18, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT01179048 at 2026-07-30T20:48:52.462Z. Its registry update date was 2019-07-17, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02042196 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-07-11, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT02833857 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT03846180 at 2026-07-30T20:48:52.443Z. Its registry update date was 2019-07-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03051087 at 2026-11-15T22:03:26.540Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT01919697 at 2026-07-30T20:48:52.437Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT03759301 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-06-24, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT03466567 at 2026-07-30T20:50:35.918Z. Its registry update date was 2019-06-19, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02387359 at 2026-07-30T20:50:35.893Z. Its registry update date was 2019-06-14, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT02493452 at 2026-07-30T20:50:35.872Z. Its registry update date was 2019-06-14, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT02075606 at 2026-07-30T20:50:35.870Z. Its registry update date was 2019-06-07, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02060383 at 2026-07-30T20:52:10.194Z. Its registry update date was 2019-05-29, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01429987 at 2026-07-30T20:52:10.191Z. Its registry update date was 2019-05-28, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT01722318 at 2026-07-30T20:52:10.190Z. Its registry update date was 2019-05-28, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT01962870 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-05-24, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01611935 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-05-21, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00461552 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-05-09, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02911818 at 2026-07-30T20:52:10.188Z. Its registry update date was 2019-05-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03930069 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-04-29, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT03586843 at 2026-11-16T17:46:45.897Z. Its registry update date was 2019-04-16, and PeptideScanner's reviewed identity mapping was efinopegdutide.
PeptideScanner retained ClinicalTrials.gov record NCT01785875 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-04-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT02239523 at 2026-07-30T20:53:39.666Z. Its registry update date was 2019-04-05, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02883595 at 2026-11-15T22:10:40.222Z. Its registry update date was 2019-04-04, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT01696877 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-03-28, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT02865681 at 2026-11-16T01:35:57.709Z. Its registry update date was 2019-03-19, and PeptideScanner's reviewed identity mapping was nafarelin.
PeptideScanner retained ClinicalTrials.gov record NCT00314795 at 2026-11-16T17:45:11.119Z. Its registry update date was 2019-03-14, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01800877 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-03-12, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01318278 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-02-20, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00765999 at 2026-07-30T20:56:08.251Z. Its registry update date was 2019-02-15, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT02584231 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-02-06, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT03824002 at 2026-07-30T20:57:18.709Z. Its registry update date was 2019-01-31, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02493517 at 2026-07-30T20:57:18.712Z. Its registry update date was 2019-01-29, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01731912 at 2026-11-15T21:52:09.579Z. Its registry update date was 2019-01-18, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT02472782 at 2026-07-30T20:57:18.711Z. Its registry update date was 2019-01-10, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02685033 at 2026-11-16T17:37:42.807Z. Its registry update date was 2019-01-04, and PeptideScanner's reviewed identity mapping was dalbavancin.